Time filter

Source Type

Tianjin, China

Prosvicova J.,County Hospital | Lukesova S.,County Hospital | Lukesova S.,Charles University | Kopecky J.,University of Hradec Kralove | And 13 more authors.
Biomedical Papers | Year: 2015

Background. Malignant melanoma in the gastrointestinal tract may be primary or metastatic. Mucosal melanoma is a quite rare and aggressive disease, growing hidden and diagnosed with a certain delay which makes treatment difficult. Case Report. The authors present the first patient with c-kit exon 11 mutated primary esophageal melanoma treated with oral tyrosine kinase inhibitor masitinib. A 55-year-old-man presented with esophageal melanoma metastising into visceral organs and to the brain. The patient showed objective and clinical significant therapeutic response to masitinib. After initiation of masitinib, dysphagia and odynophagia disappeared within 1 week. Following 1 month of treatment, computed tomography showed a regression in the number and size of brain metastatic lesions and regression in visceral lesions. This therapeutic response, despite the aggressive disease on treatment initiation, effectively enabled the patient to have 6 months of quality life. Conclusion. This report corroborates the plausibility of treating advanced melanoma carrying a mutation of KIT with masitinib. It also raises the question of masitinib treatment beyond progression. Additionally, the observed masitinib treatment effect on the brain suggests accumulation of therapeutically relevant concentration of masitinib in the central nervous system. This observation has possible ramifications for treatment of intracranial neoplasms. © 2015, PALACKY UNIV. All rights reserved. Source

Riss S.,Medical University of Vienna | Weiser F.A.,Endoscopic Center | Schwameis K.,Medical University of Vienna | Mittlbock M.,Medical University of Vienna | Stift A.,Medical University of Vienna
Colorectal Disease | Year: 2011

Aim There are few studies into the quality of life of patients with haemorrhoids. The aim of this study was to assess the quality of life of patients with haemorrhoids in an adult general population. Method Participants, who attended the Austrian nationwide healthcare programme for colorectal cancer screening at four medical institutions, were enrolled prospectively between 2008 and 2009. A colonoscopy was performed in all patients. Haemorrhoids were classified according to an international grading system and defined as symptomatic in cases with bleeding, itching, soiling or pain. Quality of life was measured by the Short Form-12 Health Survey. Results Of 976 participants, 380 patients (39%) had haemorrhoids. The median physical health score was 52.6 (range 20.6-61.3) in the symptomatic and 53.2 (range 16.2-61.3) in the asymptomatic group (P=0.7993). The median mental health score showed also no significant difference between both groups [symptomatic group, 52.8 (range 12.4-62.6); asymptomatic group, 54.8 (range 18.7-67.2); P=0.0738]. Conclusion Haemorrhoids, irrespective of their degree, do not influence quality of life measured by the Short Form-12 Health Survey. © 2011 The Authors. Colorectal Disease © 2011 The Association of Coloproctology of Great Britain and Ireland. Source

Rudolph H.U.,University of Mannheim | Post S.,University of Mannheim | Schluter M.,University of Mannheim | Seitz U.,Endoscopic Center | And 2 more authors.
Scandinavian Journal of Gastroenterology | Year: 2011

Endoscopic stenting (ES) is a minimally invasive alternative to surgical gastroenterostomy (GE) for palliation of malignant gastroduodenal obstructions. This consecutive, retrospective analysis compares the clinical outcome of all patients undergoing ES or GE in the same period. Methods. ES was performed at the Endoscopy Department, University Hospital Mannheim or at the Interdisciplinary Endoscopy Department, University Hospital Hamburg-Eppendorf. GE was performed at the Surgical Department, University Hospital Mannheim. All palliative ES or GE on patients with malignant gastroduodenal obstruction without earlier gastric resections between January 2001 and April 2007 were evaluated. Main outcome measurements were ability of solid food intake (gastric outlet obstruction score), persistence of nausea and vomiting (gut function score), length of hospital stay, morbidity, mortality and re-interventions. Results. A total of 44 ES and 43 GE were performed. Nausea and vomiting - measured by means of the gut function score - persisted in significantly more patients in the GE group than in those who underwent stent placement (p = 0.0102). The gastric outlet obstruction score at discharge from the hospital revealed no significant difference in the ability of solid food intake between the groups. The hospital stay was significantly longer in the GE group (p = 0.0003). There was no significant difference in mortality and the rates of complications and re-interventions. Conclusion. In this study, ES is a generally equivalent - and in several points superior - alternative to GE for palliation of malignant gastroduodenal obstruction. ES seems to be the less invasive alternative for symptomatic patients. GE has good results in patients with longer survival and can be practiced within abdominal explorations. © 2011 Informa Healthcare. Source

Feng X.-J.,Endoscopic Center | Che Z.,Minimally Invasive Center | Qin M.-F.,Minimally Invasive Center
World Chinese Journal of Digestology | Year: 2014

AIM: To establish and evaluate an adjustable cholestatic liver fibrosis animal model induced by bile duct ligation in vitro.METHODS: Thirty male Wistar rats were randomly divided into three groups, namely, a sham operation group (A, n = 5), an in vivo bile duct ligation group (B, n = 5) and an in vitro adjustable bile duct ligation group (C, n = 5). Rats in each group were sacrificed 7 and 10 days after successful modelling, respectively. The gross morphology and morphological changes of the liver were observed.RESULTS: The relative expression of α-smooth muscle actin (α-SMA) mRNA in groups B and C significantly increased compared with group A on days 7 and 10 after modelling (group B: 5.95 ± 1.21 vs 8.55 ± 1.34, 5.01 ± 0.27 vs 8.06 ± 0.21, P < 0.05; group C: 6.62 ± 1.25 vs 8.55 ± 1.34, 5.14 ± 0.90 vs 8.06 ± 0.21, P < 0.05), although there were no significant differences between groups B and C (6.62 ± 1.25 vs 5.95 ± 1.21, 5.14 ± 0.90 vs 5.01 ± 0.27, P > 0.05). The expression of COL1 and α-SMA genes showed similar trends to α-SMA mRNA expression.CONCLUSION: The animal model of cholestatic liver fibrosis induced by adjustable bile duct ligation in vitro is a stable and reliable model, with advantages of simplicity, short processing cycle, and easy for intervention. © 2014 Baishideng Publishing Group Inc. All rights reserved. Source

Jianqin S.,Fudan University | Leiming X.,Shanghai JiaoTong University | Lu X.,Endoscopic Center | Yelland G.W.,Monash University | And 3 more authors.
Nutrition Journal | Year: 2016

Background: Cows' milk generally contains two types of β-casein, A1 and A2 types. Digestion of A1 type can yield the peptide β-casomorphin-7, which is implicated in adverse gastrointestinal effects of milk consumption, some of which resemble those in lactose intolerance. This study aimed to compare the effects of milk containing A1 β-casein with those of milk containing only A2 β-casein on inflammation, symptoms of post-dairy digestive discomfort (PD3), and cognitive processing in subjects with self-reported lactose intolerance. Methods: Forty-five Han Chinese subjects participated in this double-blind, randomized, 2 × 2 crossover trial and consumed milk containing both β-casein types or milk containing only A2 β-casein. Each treatment period was 14 days with a 14-day washout period at baseline and between treatment periods. Outcomes included PD3, gastrointestinal function (measured by smart pill), Subtle Cognitive Impairment Test (SCIT), serum/fecal laboratory biomarkers, and adverse events. Results: Compared with milk containing only A2 β-casein, the consumption of milk containing both β-casein types was associated with significantly greater PD3 symptoms; higher concentrations of inflammation-related biomarkers and β-casomorphin-7; longer gastrointestinal transit times and lower levels of short-chain fatty acids; and increased response time and error rate on the SCIT. Consumption of milk containing both β-casein types was associated with worsening of PD3 symptoms relative to baseline in lactose tolerant and lactose intolerant subjects. Consumption of milk containing only A2 β-casein did not aggravate PD3 symptoms relative to baseline (i.e., after washout of dairy products) in lactose tolerant and intolerant subjects. Conclusions: Consumption of milk containing A1 β-casein was associated with increased gastrointestinal inflammation, worsening of PD3 symptoms, delayed transit, and decreased cognitive processing speed and accuracy. Because elimination of A1 β-casein attenuated these effects, some symptoms of lactose intolerance may stem from inflammation it triggers, and can be avoided by consuming milk containing only the A2 type of beta casein. Trial registration: ClinicalTrials.gov/NCT02406469 © 2016 Jianqin et al. Source

Discover hidden collaborations